GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with..
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with..
Annual awards celebrate excellence in California’s life sciences sector
SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE..
New research in the journal Nature Communications gives scientists an important window into how Ebola virus replicates inside..